1997
DOI: 10.3168/jds.s0022-0302(97)76006-5
|View full text |Cite
|
Sign up to set email alerts
|

Field Trials of a Vaccine Against Bovine Mastitis. 1. Evaluation in Heifers

Abstract: A vaccine was developed against bovine mastitis based on inactivated, highly encapsulated Staphylococcus aureus cells; a crude extract of Staph. aureus exopolysaccharides; and inactivated, unencapsulated Staph, aureus and Streptococcus spp. cells. This vaccine was tested on 30 heifers during a 7-mo period. The 30 heifers were randomly assigned to three groups of 10 heifers each. The prepartum group received two injections of the vaccine at 8 and 4 wk before calving, and the postpartum group received two inject… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
35
2
3

Year Published

2002
2002
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 65 publications
(49 citation statements)
references
References 24 publications
5
35
2
3
Order By: Relevance
“…Indeed, culling of chronically infected cows, dry cow therapy and antibiotic treatment are recommended in the control of S. aureus infection [13,22]. This was exemplified with the lower R 0 in controlled (R 0 = 0.71) than uncontrolled (R 0 = 3.74) herds under the genetic Structure 1.…”
Section: Non-genetic Management Of Infectious Diseasesmentioning
confidence: 91%
“…Indeed, culling of chronically infected cows, dry cow therapy and antibiotic treatment are recommended in the control of S. aureus infection [13,22]. This was exemplified with the lower R 0 in controlled (R 0 = 0.71) than uncontrolled (R 0 = 3.74) herds under the genetic Structure 1.…”
Section: Non-genetic Management Of Infectious Diseasesmentioning
confidence: 91%
“…Those supplements to the bacterin are considered to enhance its efficacy. A vaccine consisting of inactivated, highly encapsulated S. aureus cells, inactivated unencapsulated S. aureus and crude extract of S. aureus exopolysaccharides was tested in heifers and dairy cows in field trials Giraudo et al, 1997). This vaccine was able to reduce intramammary infection rates but did not offer full protection.…”
Section: Discussionmentioning
confidence: 99%
“…Podeljena su mišljenja o aplikaciji vakcine u supramamarni limfni čvor, zbog jakog lokalnog zapaljenja limfnog čvora, koji otiče i veoma je bolan (Nordhaug, 1994;Hoedermaker, 1999). Zbog toga se sve više istraživača opredeljuje za davanje vakcine parenteralno-subkutano u regiju vrata ili subkutano u regiju limfnog čvora, jer je takav način jednostavan za aplikaciju, a izbegnute su i lokalne reakcije tkiva na vakcinu (Giraudo, 1997;Watson, 1996).…”
Section: Ključne Reči: Mastitis Vakcina Staphylococcus Aureusunclassified
“…Eksperimentalne grupe od 1 do 5 su primile inaktivisanu bakterijsku ćeliju S. aureus (10 10 bakterija u dozi), nosač vakcine je bio aluminijum hiodroksid (grupe 1, 2, 4, 5) i komercijalni nosač vakcine (grupa 3). Eksperimentalne grupe 6, 7, 8 i 9 u sastavu vakcine su primile površinski polisaharid S. aureus-a u dozi od 2 mg, a nosači su bili liposomal (6,7,9) i mikropartkule u grupi 8. Kontrolna grupa nije primila vakcinu, već samo fosfatni pufer.…”
Section: Ključne Reči: Mastitis Vakcina Staphylococcus Aureusunclassified